Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,14%
1 095,36
+1,55
+0,14%
—1 093,811 096,521 100,221 093,20——
SIXC
Communications
SIXC
Communications
SIXC
+0,33%
610,79
+2,02
+0,33%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,10%
1 240,95
-13,86
-1,10%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,63%
1 749,96
-11,15
-0,63%
—1 761,111 764,271 766,881 745,39——
SIXM
Financials
SIXM
Financials
SIXM
-0,07%
642,11
-0,47
-0,07%
—642,58644,87648,48641,40——
SIXR
Staples
SIXR
Staples
SIXR
-0,21%
849,36
-1,77
-0,21%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,22%
217,50
-0,48
-0,22%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,64%
3 264,57
+52,74
+1,64%
—3 211,833 227,213 267,763 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,48%
944,43
-4,55
-0,48%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,22%
1 471,27
-3,25
-0,22%
—1 474,521 479,031 481,041 469,17——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,65%
2 407,63
+15,51
+0,65%
—2 392,122 396,952 421,222 382,32——
4502:TYO
Takeda Pharmaceutical Co Ltd
5 239,00 JP¥
-0,59%
(-31,00) 1D
1-май, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4502...
Open
5 260 JP¥
High
5 260 JP¥
Low
5 191 JP¥
Mkt. cap
8,34 трлн
Avg. vol.
4,37 млн
Volume
2,63 млн
Dividend
3,78%
Quarterly dividend
49 JP¥
Ex dividend date
2025-ж., 29-сен.
P/E ratio
72,50
52-wk high
6 033 JP¥
52-wk low
4 000 JP¥
EPS
72 JP¥
Shares outstanding
784,48 млн
No. of employees
47 миң
News stories
From sources across the web
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOChristophe Weber | Christophe Weber
Employees47,5 миң
Founded1781-ж., 12-июн.
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Last report
2026-ж., 29-янв.
Fiscal Period
Q3 2026
Normalized EPS / Estimate
-/ -JPY
Revenue / Estimate
1,19 трлн/ (1,20 трлн est.)JPY
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
1,05 трлн
1,11 трлн
1,11 трлн
1,19 трлн
Cost of goods sold
373,28 млд
384,68 млд
380,06 млд
401,15 млд
Cost of revenue
373,28 млд
384,68 млд
380,06 млд
401,15 млд
Research and development expenses
216,01 млд
143,89 млд
161,48 млд
175,23 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
295,83 млд
255,88 млд
253,55 млд
282,78 млд
Operating expense
557,10 млд
535,14 млд
562,57 млд
661,30 млд
Total operating expenses
930,38 млд
919,82 млд
942,63 млд
1,06 трлн
Operating income
123,02 млд
186,86 млд
170,17 млд
129,25 млд
Other non operating income
-24,86 млд
-77,96 млд
77,96 млд
-294,52 млд
EBT including unusual items
-107,30 млд
150,63 млд
28,17 млд
133,86 млд
EBT excluding unusual items
100,18 млд
152,93 млд
128,86 млд
114,17 млд
Income tax expense
-4,20 млд
26,35 млд
39,90 млд
30,13 млд
Effective tax rate
3,92%
17,49%
141,64%
22,51%
Other operating expenses
-91,26 млд
6,03 млд
16,12 млд
67,13 млд
Net income
-103,16 млд
124,24 млд
-11,80 млд
103,64 млд
Net profit margin
-9,79%
11,23%
-1,06%
8,70%
Earnings per share
-
-
-
-
Interest and investment income
9,85 млд
73,76 млд
43,92 млд
278,65 млд
Interest expense
-7,82 млд
-29,20 млд
-161,10 млд
-
Net interest expenses
2,03 млд
44,56 млд
-117,18 млд
278,65 млд
Depreciation and amortization charges
-
-
-
-
EBITDA
221,72 млд
368,50 млд
355,15 млд
182,70 млд
Gain or loss from assets sale
-2,39 млд
-17,32 млд
303,00 млн
358,00 млн
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer